學術產出-Periodical Articles

Article View/Open

Publication Export

Google ScholarTM

政大圖書館

Citation Infomation

題名 On tier method for assessment of individual bioequivalence
作者 Ju, Huey L.
貢獻者 統計系
關鍵詞 Prescribility; Switchability; Bioavailability; Interval hypothesis
日期 1997
上傳時間 14-Dec-2015 17:33:45 (UTC+8)
摘要 The bioavailability and bioequivalence between drug products has become an important subject in drug development. The average bioavailability of the test (T) and the reference (R) products is currently specified in the FDA guidelines to be used for assessing the bioequivalence of the drug products. However, it has been recognized that the safety for the substitution of a reference drug product with a test drug product in patients, whose concentration may have been titrated to a steady efficacious and safe level, could be a concern. Therefore, it is suggested that individual bioequivalence within each subject be assessed to assure the safety of the drug switchability. This paper examines the statistical properties of TIER procedure that Anderson and Hauck (1) proposed to assess individual bioequivalence. It is shown that Anderson and Hauck`s procedure could be improved by imposing some distribution assumption such as lognormal distribution for assessment of individual bioequivalence. This paper also compares the relative performance of the individual bioequivalence based on TIER procedure and the average bioequivalence based on two one-sided tests procedure suggested by Schuirmann (2). The relationship between equivalence limits for the improved TIER procedure and average bioequivalence is also examined.
關聯 Journal of Biopharmaceutical Statistics, Volume 7, Issue 1, pages 63-85
資料類型 article
DOI http://dx.doi.org/10.1080/10543409708835170
dc.contributor 統計系-
dc.creator (作者) Ju, Huey L.-
dc.date (日期) 1997-
dc.date.accessioned 14-Dec-2015 17:33:45 (UTC+8)-
dc.date.available 14-Dec-2015 17:33:45 (UTC+8)-
dc.date.issued (上傳時間) 14-Dec-2015 17:33:45 (UTC+8)-
dc.identifier.uri (URI) http://nccur.lib.nccu.edu.tw/handle/140.119/79651-
dc.description.abstract (摘要) The bioavailability and bioequivalence between drug products has become an important subject in drug development. The average bioavailability of the test (T) and the reference (R) products is currently specified in the FDA guidelines to be used for assessing the bioequivalence of the drug products. However, it has been recognized that the safety for the substitution of a reference drug product with a test drug product in patients, whose concentration may have been titrated to a steady efficacious and safe level, could be a concern. Therefore, it is suggested that individual bioequivalence within each subject be assessed to assure the safety of the drug switchability. This paper examines the statistical properties of TIER procedure that Anderson and Hauck (1) proposed to assess individual bioequivalence. It is shown that Anderson and Hauck`s procedure could be improved by imposing some distribution assumption such as lognormal distribution for assessment of individual bioequivalence. This paper also compares the relative performance of the individual bioequivalence based on TIER procedure and the average bioequivalence based on two one-sided tests procedure suggested by Schuirmann (2). The relationship between equivalence limits for the improved TIER procedure and average bioequivalence is also examined.-
dc.format.extent 124 bytes-
dc.format.mimetype text/html-
dc.relation (關聯) Journal of Biopharmaceutical Statistics, Volume 7, Issue 1, pages 63-85-
dc.subject (關鍵詞) Prescribility; Switchability; Bioavailability; Interval hypothesis-
dc.title (題名) On tier method for assessment of individual bioequivalence-
dc.type (資料類型) article-
dc.identifier.doi (DOI) 10.1080/10543409708835170-
dc.doi.uri (DOI) http://dx.doi.org/10.1080/10543409708835170-